Physician profile
Judith Yu
NPI 1336791631
$14,287.68
in general payments reported to CMS, 2019-2025
61 companies · $3,170 in 2025
The $3,170 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,806 · 2022: $2,474 · 2023: $3,276 · 2024: $3,562 · 2025: $3,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,008.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,161.40 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $2,161.58 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $828.74 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $739.48 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Lundbeck LLC | $594.43 | 2023-2025 | Vyepti, Rexulti |
| Pfizer INC. | $546.80 | 2023-2025 | |
| Biogen, INC. | $518.70 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $441.63 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $391.65 | 2021-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $312.98 | 2021-2025 | |
| Sk Life Science, INC. | $266.40 | 2021-2025 | |
| Genzyme Corporation | $257.47 | 2022-2025 | |
| Amgen INC. | $252.84 | 2021-2025 | Aimovig, Uplizna |
| Alexion Pharmaceuticals, INC. | $245.74 | 2021-2025 | Ultomiris, Koselugo |
| Otsuka America Pharmaceutical, INC. | $243.04 | 2023-2025 | Rexulti |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.